News

This authorisation marks a first TROP2 ADC and the first fully approved domestically developed ADC for marketing in China. The approval of sac-TMT is based on the outcomes

The vaccine, which is approved for adults currently, may soon be available for use in adolescents aged 12 to 17 years if the extension is granted. This move

This investigational ribonucleic acid interference (RNAi) therapeutic is aimed at treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The FDA has set a prescription drug user fee act (PDUFA) action

The approval makes the company the first commercial biotech to receive such a license for this cell therapy type. Derived from the umbilical cord blood of humans, the

The funding is set to enhance the company’s C1 protein production platform to enable rapid, cost-effective production of mAbs. This initiative focuses on diseases like RSV and malaria,

This partnership aims to address the global obesity epidemic by fast-tracking an innovative therapy that could improve the lives of millions. It includes the progression of LAE102 through

This small interfering ribonucleic acid (RNA)[siRNA] therapy is designed to combat one of the ALS subtypes, FUS-ALS, by reducing FUS protein levels. RAG-21 leverages RNA interference (RNAi) technology

This rare genetic disease currently lacks FDA-approved treatments, making the submission a significant milestone. Plozasiran, also known as ARO-APOC3, is an investigational RNA interference (RNAi) therapeutic. It aims

Under the agreement, Kaken has secured an option to acquire commercial rights to the antibody in select Asian territories. In return, the company will fund the preclinical and